Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL410098 | 0.83 | TNK2 (0.52) | TNK2ABL1SRCRETKDR | |
| SCHEMBL10445945 | 0.83 | PDE1A (0.39) | TNK2ABL1SRCBTKTLR7 | |
| SCHEMBL18099733 | 0.82 | ABL1 (0.53) | TNK2ABL1SRCRETKDR | |
| SCHEMBL12437111 | 0.82 | TNK2 (0.51) | TNK2ABL1SRCRETKDR | |
| SCHEMBL13977159 | 0.81 | TNK2 (0.39) | TNK2ABL1SRCRETKDR | |
| SCHEMBL19733424 | 0.80 | TNK2 (0.49) | TNK2ABL1SRCRETKDR | |
| SCHEMBL463424 | 0.79 | BTK (0.50) | TNK2ABL1SRCBTKIGF1R | |
| SCHEMBL13541945 | 0.76 | BTK (0.39) | TNK2ABL1SRCBTKIGF1R | |
| SCHEMBL16748839 | 0.74 | TNK2 (0.69) | TNK2ABL1SRCRETKDR | |
| SCHEMBL13541946 | 0.73 | TNK2 (0.52) | TNK2ABL1SRCBTKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130012525-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | PHARMACYLICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120329130-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-8236812-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | PHARMACYCLICS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-7960396-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. A DELAWARE CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-7732454-B2 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165328-A1 | INHIBITORS OF B LYMPHOCYTE KINASE | BLK, DCK, LTK | TNK2 96/4885ABL1 60/4885SRC 287/4885 |
| US-20130012525-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS | BTK, ABL1, LYN | TNK2 112/4885ABL1 2/4885SRC 6/4885 |
| US-20130035334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TNK2 25/4885ABL1 1/4885SRC 17/4885 |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TNK2 101/4885ABL1 5/4885SRC 7/4885 |
| US-20120101114-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TNK2 25/4885ABL1 1/4885SRC 17/4885 |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TNK2 101/4885ABL1 5/4885SRC 7/4885 |
| US-20130018060-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TNK2 25/4885ABL1 1/4885SRC 17/4885 |
| US-20110008257-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TNK2 101/4885ABL1 5/4885SRC 7/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | TNK2 276/4885ABL1 15/4885SRC 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.